Document is current
Any future updates will be listed below
-
Authors
Gallage, Suchira https://orcid.org/0000-0002-1956-3597
Irvine, Elaine E.
Barragan Avila, Jose Efren https://orcid.org/0000-0002-9348-909X
Reen, Virinder
Pedroni, Silvia M. A.
Duran, Imanol https://orcid.org/0000-0001-6615-3788
Ranvir, Vikas https://orcid.org/0000-0002-0437-6908
Khadayate, Sanjay https://orcid.org/0000-0003-4278-6403
Pombo, Joaquim
Brookes, Sharon
Heide, Danijela
Dharmalingham, Gopuraja
Choudhury, Agharul I.
Singh, Indrabahadur
Herranz, Nicolás
Vernia, Santiago https://orcid.org/0000-0001-6728-5555
Heikenwalder, Mathias https://orcid.org/0000-0002-3135-2274
Gil, Jesús https://orcid.org/0000-0002-4303-6260
Withers, Dominic J. https://orcid.org/0000-0002-8009-7521
- License Information
-
More Information
Article History
Received: 14 November 2022
Accepted: 30 July 2024
First Online: 29 August 2024
Competing interests
: J.G. has been a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma and Merck KGaA. Pfizer and Unity Biotechnology have funded research in J.G.’s laboratory (unrelated to the work presented here). J.G. owns equity in Geras Bio. J.G. is a named inventor in Medical Research Council and Imperial College patents, both related to senolytic therapies (the patents are not related to the work presented here). The remaining authors declare no competing interests.
